Responsiveness to Levodopa in epsilon-sarcoglycan deletions

Movement Disorders

Volumn 24, Issue 3, 2009, Pages 425-428

  San Luciano, Marta ^a   Ozelius, Laurie ^b   Sims, Katherine ^c   Raymond, Deborah ^a   Liu, Liu ^b   Saunders Pullman, Rachel ^a,d  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Dystonia; Epsilon sarcoglycan; Levodopa; Myoclonus

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CLONAZEPAM; EPSILON SARCOGLYCAN; LEVODOPA; TRIHEXYPHENIDYL; ANTIPARKINSON AGENT; SARCOGLYCAN;

ADOLESCENT; ANAMNESIS; ARTICLE; CASE REPORT; CHILD; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; FAMILY HISTORY; FEMALE; GENE DELETION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; MAINTENANCE DRUG DOSE; MALE; MYOCLONUS DYSTONIA; PRIORITY JOURNAL; SCHOOL CHILD; DYSTONIA; GENETICS; MYOCLONUS;

ADOLESCENT; ANTIPARKINSON AGENTS; CHILD; DYSTONIA; FEMALE; GENE DELETION; HUMANS; LEVODOPA; MALE; MYOCLONUS; SARCOGLYCANS;

EID: 67449129148     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22375     Document Type: Article

References (24)

1. Saunders-Pullman R, Shriberg J, Heiman G, et al. Myoclonus dystonia: possible association with obsessive-compulsive disorder and alcohol dependence. Neurology 2002;58:242-245.
2. Hess CW, Raymond D, Aguiar Pde C, et al. Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology 2007;68:522-524.
3. Asmus F, Zimprich A, Tezenas Du Montcel S, et al. Myoclonusdystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol 2002;52:489-492.
4. Nygaard TG, Raymond D, Chen C, et al. Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol 1999;46:794-798.
5. Trottenberg T, Meissner W, Kabus C, et al. Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonusdystonia syndrome. Mov Disord 2001;16:769-771.
6. Frucht SJ, Bordelon Y, Houghton WH, Reardan D. A pilot tolerability and ef.cacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord 2005;20:1330-1337.
7. Frucht SJ, Houghton WC, Bordelon Y, Greene PE, Louis ED. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology 2005;65:1967-1969.
8. Pueschel SM, Friedman JH, Shetty T. Myoclonic dystonia. Childs Nerv Syst 1992;8:61-66.
9. Lim LL, Ahmed A. Limited efficacy of levetiracetam on myoclonus of different etiologies. Parkinsonism Relat Disord 2005;11: 135-137.
10. Chadwick D, Hallett M, Harris R, Jenner P, Reynolds EH, Marsden CD. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Brain 1977;100:455-487.
11. Cif L, Valente EM, Hemm S, et al. Deep brain stimulation in myoclonus-dystonia syndrome. Mov Disord 2004;19:724-727.
12. Magarinos-Ascone CM, Regidor I, Martinez-Castrillo JC, Gomez-Galan M, Figueiras-Mendez R. Pallidal stimulation relieves myoclonus-dystonia syndrome. J Neurol Neurosurg Psychiatry 2005;76:989-991.
13. Marsden CD. Drug treatment of diseases characterized by abnormal movements. Proc R Soc Med 1973;66:871-873.
14. Yokoi F, Dang MT, Li J, Li Y. Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in epsilon-sarcoglycan deficient mice. J Biochem (Tokyo) 2006; 140: 141-146.
15. Asmus F, Salih F, Hjermind LE, et al. Myoclonus-dystonia due to genomic deletions in the epsilon-sarcoglycan gene. Ann Neurol 2005;58:792-797.
16. Raymond D, Saunders-Pullman R, de Carvalho Aguiar P, et al. Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with epsilon-sarcoglycan mutations. Mov Disord 2008;23:588-592.
17. Hjermind LE, Werdelin LM, Eiberg H, Krag-Olsen B, Dupont E, Sorensen SA. A novel mutation in the epsilon-sarcoglycan gene causing myoclonus-dystonia syndrome. Neurology 2003;60: 1536-1539.
18. Esapa CT, Waite A, Locke M, et al. SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan traf.cking to the plasma membrane: modulation by ubiquitination and torsinA. Hum Mol Genet 2007;16:327-342.
19. Kock N, Kasten M, Schule B, et al. Clinical and genetic features of myoclonus-dystonia in 3 cases: a video presentation. Mov Disord 2004;19:231-234.
20. Leuzzi V, Carducci C, Carducci C, Cardona F, Artiola C, Antonozzi I. Autosomal dominant GTP-CH de.ciency presenting as a dopa-responsive myoclonus-dystonia syndrome. Neurology 2002; 59:1241-1243.
21. Tsirikos AI, Carr LJ, Noordeen HH. Variability of clinical expression and evolution of spinal deformity in a family with late detection of dopa-responsive dystonia. Dev Med Child Neurol 2004;46:128-137.
22. DeBerardinis RJ, Conforto D, Russell K, et al. Myoclonus in a patient with a deletion of the e-sarcoglycan locus on chromosome 7q21. Am J Med Gen 2003;121A:31-36.
23. Asmus F, Hjermind LE, Dupont E, et al. Genomic deletion size at the Epsilon-Sarcoglycan locus determines the clinical phenotype. Brain 2007;130:2736-2745.
24. Han F, Racacho L, Yang H, et al. Large deletions account for an increasing number of mutations in SGCE. Mov Disord 2008;23: 456-460.